In Vivo Efficacy of Contact Lens Drug-Delivery Systems in Glaucoma Management. A Systematic Review
Source abstract
Abstract
Adherence is crucial in medical glaucoma therapy, although half of the patients skip eyedrops. In recent years alternative drug-delivery systems have been developed. One of the most promising seems the contact lens (CL). This systematic review aims to present the in vivo efficacy of different CL drug-delivery systems. A total of 126 studies were identified following a literature search adhering to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. After full-text evaluation, 19 studies about CL drug-delivery systems were included. To date, the following drug-delivery systems have been investigated in vivo: drug-soaked CL, CL with physical barriers (vitamin E), molecularly imprinted CL, CL with implants, and nanoparticle-loaded CL. Nanoparticle-loaded CL and CL with implants seem the most promising drug-delivery systems, although initial burst drug release and patient acceptance may limit their widespread use in current practice. Clinical trials are warranted to understand the role of CL as a drug-delivery system in improving glaucomatous patient care.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Glaucoma and retinal disorders · Ocular Surface and Contact Lens · Corneal surgery and disorders
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Ophthalmology, Department of Surgical, Medical, Molecular Pathology and of the Critical Area, University of Pisa, 56126 Pisa, Italy
References (88)
Show source-provided references
1. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis10.1016/j.ophtha.2014.05.013 ↗
2. The probability of blindness from open-angle glaucoma10.1016/S0161-6420(98)91133-2 ↗
3. (2017). European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition—Part 1 Supported by the EGS Foundation. Br. J. Ophthalmol., 101, 1–72.10.1136/bjophthalmol-2016-EGSguideline.001 ↗
4. (2017). European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition—Chapter 3: Treatment principles and options Supported by the EGS Foundation. Part 1 Foreword Introd. Gloss. Chapter 3 Treat. Princ. Options, 101, 130–195.10.1136/bjophthalmol-2016-EGSguideline.003 ↗
5. Current management of glaucoma10.5694/mja2.50020 ↗
6. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study10.1016/j.ophtha.2008.09.004 ↗
7. Glaucoma Adherence-From Theriac to the Future10.1016/j.ajo.2018.04.002 ↗
8. Comparisons of Self-reported Glaucoma Medication Adherence with a New Wireless Device: A Pilot Study10.1097/IJG.0000000000000777 ↗
9. Compliance barriers in glaucoma: A systematic classification10.1097/00061198-200310000-00001 ↗
10. Ocular symptoms and signs with preserved and preservative-free glaucoma medications10.1177/112067210701700311 ↗
11. Allergic contact dermatitis caused by topical ophthalmic medications: Keep an eye on it!10.1111/cod.13209 ↗
12. Drop instillation and glaucoma10.1097/ICU.0000000000000451 ↗
13. Adherence and persistence with glaucoma therapy10.1016/j.survophthal.2008.08.002 ↗
14. Figus, M., Agnifili, L., Lanzini, M., Brescia, L., Sartini, F., Mastropasqua, L., and Posarelli, C. (2020). Topical preservative-free ophthalmic treatments: An unmet clinical need. Expert Opin. Drug Deliv.10.1080/17425247.2021.1860014 ↗
15. Ocular preservatives: Associated risks and newer options10.1080/15569520902995834 ↗
16. The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye
17. New devices for dispensing ophthalmic treatments may be the key to managing the life cycles of established products
18. Kompella, U.B., Hartman, R.R., and Patil, M.A. (2020). Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma. Prog. Retin. Eye Res., 100901.10.1016/j.preteyeres.2020.100901 ↗
19. Souto, E.B., Dias-Ferreira, J., Lopez-Machado, A., Ettcheto, M., Cano, A., Camins Espuny, A., Espina, M., Garcia, M.L., and Sanchez-Lopez, E. (2019). Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents. Pharmaceutics, 11.10.3390/pharmaceutics11090460 ↗
20. Ocular drug delivery10.1208/s12248-010-9183-3 ↗
21. Peral, A., Martínez Águila, A., Pastrana, C., Huete-Toral, F., Carpena-Torres, C., and Carracedo, G. (2020). Contact Lenses as Drug Delivery System for Glaucoma: A Review. Appl. Sci., 10.10.3390/app10155151 ↗
22. Contact Lenses Yesterday, Today, and the Best Yet to Come
23. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement10.1016/j.jclinepi.2009.06.005 ↗
24. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables10.1016/j.jclinepi.2010.04.026 ↗
25. Auditing the implementation of SIGN (Scottish Intercollegiate Guidelines Network) clinical guidelines10.1108/09526869910297331 ↗
26. Evidence-based mechanistic reasoning10.1258/jrsm.2010.100146 ↗
27. Animal research: Reporting in vivo experiments: The ARRIVE guidelines10.1111/j.1476-5381.2010.00872.x ↗
28. Quality assessment of reporting of animal studies on pathogenesis and treatment of peri-implant mucositis and peri-implantitis. A systematic review using the ARRIVE guidelines10.1111/j.1600-051X.2011.01838.x ↗
29. Alemán-Laporte, J., Alvarado, G., Sa Garcia-Gomes, M., Fonseca Brasil Antiorio, A.T., Zúñiga-Montero, M., and Cabrera Mori, C.M. (2019). Quality of Adherence to the ARRIVE Guidelines in the Material and Methods Section in Studies Where Swine Were Used as Surgical Biomodels: A Systematic Review (2013–2018). Animals (Basel), 9.10.3390/ani9110947 ↗
30. The use of GRADE approach in systematic reviews of animal studies10.1111/jebm.12198 ↗
31. A medical device/drug delivery system for treatment of glaucoma10.1111/j.1444-0938.2009.00370.x ↗
32. Treatment of acute glaucoma
33. Ocular penetration of pilocarpine in primates10.1016/0002-9394(73)91015-5 ↗
34. Pilocarpine therapy with soft contact lenses10.1016/0002-9394(72)90062-1 ↗
35. Management of acute glaucoma with pilocarpine-soaked hydrophilic lens10.1136/bjo.58.7.674 ↗
36. Pilocarpine dispensation for the soft hydrophilic contact lens10.1136/bjo.59.8.455 ↗
37. Drug delivery by contact lens in spontaneously glaucomatous dogs10.3109/02713683.2011.630154 ↗
38. Extended drug delivery by contact lenses for glaucoma therapy10.1016/j.jconrel.2012.06.017 ↗
39. Dual drug delivery from vitamin E loaded contact lenses for glaucoma therapy10.1016/j.ejpb.2015.06.001 ↗
40. Ocular release of timolol from molecularly imprinted soft contact lenses10.1016/j.biomaterials.2004.04.030 ↗
41. Co-delivery of timolol and hyaluronic acid from semi-circular ring-implanted contact lenses for the treatment of glaucoma: In vitro and in vivo evaluation10.1039/C8BM00212F ↗
42. Multiple drug delivery from the drug-implants-laden silicone contact lens: Addressing the issue of burst drug release10.1016/j.msec.2020.110885 ↗
43. Glaucoma therapy by extended release of timolol from nanoparticle loaded silicone-hydrogel contact lenses10.1016/j.jconrel.2012.10.010 ↗
44. In vivo performance of a drug-eluting contact lens to treat glaucoma for a month10.1016/j.biomaterials.2013.09.032 ↗
45. Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys10.1016/j.ophtha.2016.06.038 ↗
46. In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery10.1016/j.jconrel.2016.02.012 ↗
47. Preparation and evaluation of a contact lens vehicle for puerarin delivery10.1163/156856209X415774 ↗
48. Effect of gold nanoparticles on timolol uptake and its release kinetics from contact lenses: In vitro and in vivo evaluation10.1016/j.actbio.2019.01.004 ↗
49. Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma10.1016/j.jconrel.2019.05.025 ↗
50. Hydrophilic Gels for Biological Use10.1038/185117a0 ↗
51. Pilocarpine administration by contact lens
52. Latanoprost uptake and release from commercial contact lenses10.1080/09205063.2019.1669126 ↗
53. Sustained drug release by contact lenses for glaucoma treatment-a review10.1016/j.jconrel.2015.01.023 ↗
54. Ocular Drug Delivery through pHEMA-Hydrogel Contact Lenses Co-Loaded with Lipophilic Vitamins10.1038/srep34194 ↗
55. Soft contact lenses capable of sustained delivery of timolol10.1002/jps.10209 ↗
56. Molecularly imprinted therapeutic contact lenses10.1517/17425241003770098 ↗
57. Imprinted soft contact lenses as norfloxacin delivery systems10.1016/j.jconrel.2006.05.003 ↗
58. Enhancing therapeutic loading and delaying transport via molecular imprinting and living/controlled polymerization10.1002/aic.11949 ↗
59. Controlled release of high molecular weight hyaluronic Acid from molecularly imprinted hydrogel contact lenses10.1007/s11095-008-9818-6 ↗
60. In vitro and in vivo evaluation of ketotifen fumarate-loaded silicone hydrogel contact lenses for ocular drug delivery10.3109/10717544.2010.522612 ↗
61. Controlled release of prednisolone acetate from molecularly imprinted hydrogel contact lenses10.1002/app.36625 ↗
62. Varela-Garcia, A., Gomez-Amoza, J.L., Concheiro, A., and Alvarez-Lorenzo, C. (2020). Imprinted Contact Lenses for Ocular Administration of Antiviral Drugs. Polymers (Basel), 12.10.3390/polym12092026 ↗
63. Drug delivery and nanoparticles:applications and hazards
64. Poly(hydroxyethyl methacrylate-co-methacrylated-beta-cyclodextrin) hydrogels: Synthesis, cytocompatibility, mechanical properties and drug loading/release properties10.1016/j.actbio.2007.12.008 ↗
65. Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment10.2147/IJN.S254792 ↗
66. Programs to optimize adherence in glaucoma10.1016/j.optm.2009.09.021 ↗
67. Emerging surgical therapy in the treatment of glaucoma10.1016/bs.pbr.2015.06.011 ↗
68. European study of the efficacy of a cross-linked gel stent for the treatment of glaucoma10.1097/j.jcrs.0000000000000065 ↗
69. Patient attitudes toward novel glaucoma drug delivery approaches10.5693/djo.01.2018.07.001 ↗
70. Agency, E.M. (2020, May 27). Emea/622721/2009. Available online: https://www.ema.europa.eu/en/documents/public-statement/emea-public-statement-antimicrobial-preservatives-ophthalmic-preparations-human-use_en.pdf.
71. Patient Acceptance of Sustained Glaucoma Treatment Strategies10.1097/IJG.0000000000000913 ↗
72. Review of Contact Lens-Related Complications10.1097/ICL.0000000000000481 ↗
73. Contact lenses and other risk factors in microbial keratitis10.1016/0140-6736(91)91231-I ↗
74. The impact of overnight wear on the risk of contact lens-associated ulcerative keratitis10.1001/archopht.1994.01090140062024 ↗
75. The vascular response to long-term extended contact lens wear10.1111/j.1444-0938.1986.tb06800.x ↗
76. Effects of long-term extended contact lens wear on the human cornea
77. Risk factors for contact lens associated microbial keratitis10.1016/S1367-0484(01)00002-9 ↗
78. Short-term adaptation of the human corneal endothelium to continuous wear of silicone hydrogel (lotrafilcon A) contact lenses after daily hydrogel lens wear10.1097/01.opx.0000168559.84788.0b ↗
79. TFOS DEWS II Tear Film Report10.1016/j.jtos.2017.03.006 ↗
80. Ocular surface changes induced by contact lens wear10.1097/00003226-200111000-00009 ↗
81. Mistaken diagnosis of keratoconus because of corneal warpage induced by hydrogel lens wear10.1097/ICO.0b013e318055e65c ↗
82. Hydrogel contact lens-induced corneal warpage10.1016/S1367-0484(03)00026-2 ↗
83. Anti-glaucoma drug-loaded contact lenses prepared using supercritical solvent impregnation10.1016/j.supflu.2010.02.007 ↗
84. Drug-Loaded Nanoparticles Embedded in a Biomembrane Provide a Dual-Release Mechanism for Drug Delivery to the Eye10.1089/jop.2016.0050 ↗
85. Thermo-sensitive nanogel-laden bicontinuous microemulsion drug-eluting contact lenses10.1002/jbm.b.34209 ↗
86. Stimulus-Responsive Contact Lens for IOP Measurement or Temperature-Triggered Drug Release10.1167/tvst.9.4.1 ↗
87. Azulene incorporation and release by hydrogel containing methacrylamide propyltrimenthylammonium chloride, and its application to soft contact lens10.1016/S0168-3659(03)00368-7 ↗
88. Application of polymer gels containing side-chain phosphate groups to drug-delivery contact lenses10.1002/app.22080 ↗